Implantica Ag Stock Fundamentals
| IMP-A-SDB | SEK 35.05 1.40 3.84% |
Implantica AG fundamentals help investors to digest information that contributes to Implantica's financial success or failures. It also enables traders to predict the movement of Implantica Stock. The fundamental analysis module provides a way to measure Implantica's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Implantica stock.
Implantica |
Implantica AG Company Operating Margin Analysis
Implantica's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Implantica Operating Margin | (24.51) % |
Most of Implantica's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Implantica AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, Implantica AG has an Operating Margin of -24.5106%. This is 30.13% lower than that of the Healthcare sector and 37.65% lower than that of the Medical Devices industry. The operating margin for all Sweden stocks is notably higher than that of the company.
Implantica AG Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Implantica's current stock value. Our valuation model uses many indicators to compare Implantica value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Implantica competition to find correlations between indicators driving Implantica's intrinsic value. More Info.Implantica AG is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Implantica's earnings, one of the primary drivers of an investment's value.Implantica Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Implantica's direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Implantica could also be used in its relative valuation, which is a method of valuing Implantica by comparing valuation metrics of similar companies.Implantica is currently under evaluation in operating margin category among its peers.
Implantica Fundamentals
| Return On Equity | -0.15 | |||
| Return On Asset | -0.0674 | |||
| Operating Margin | (24.51) % | |||
| Current Valuation | 5.38 B | |||
| Shares Owned By Institutions | 28.58 % | |||
| Revenue | 707 K | |||
| Gross Profit | (867 K) | |||
| EBITDA | (17.06 M) | |||
| Net Income | (15.36 M) | |||
| Cash And Equivalents | 147.29 M | |||
| Cash Per Share | 2.12 X | |||
| Total Debt | 142 K | |||
| Current Ratio | 53.28 X | |||
| Book Value Per Share | 0.54 X | |||
| Cash Flow From Operations | (11.47 M) | |||
| Earnings Per Share | (0.06) X | |||
| Number Of Employees | 29 | |||
| Beta | 1.34 |
About Implantica Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Implantica AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Implantica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Implantica AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Implantica AG, a medtech company, researches, develops, and sells medical implants for unmet medical needs in Switzerland. The company was founded in 2015 and is based in Vaduz, Liechtenstein. Implantica is traded on Stockholm Stock Exchange in Sweden.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Implantica Stock Analysis
When running Implantica's price analysis, check to measure Implantica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Implantica is operating at the current time. Most of Implantica's value examination focuses on studying past and present price action to predict the probability of Implantica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Implantica's price. Additionally, you may evaluate how the addition of Implantica to your portfolios can decrease your overall portfolio volatility.